FibroGen (FGEN) News Today $0.36 -0.02 (-5.33%) Closing price 04:00 PM EasternExtended Trading$0.35 -0.01 (-2.05%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period FibroGen to Report Fourth Quarter and Full Year 2024 Financial ResultsMarch 3 at 4:45 PM | globenewswire.comFibroGen (FGEN) Projected to Post Earnings on MondayFebruary 23, 2025 | americanbankingnews.comFibroGen (NASDAQ:FGEN) Coverage Initiated at StockNews.comFebruary 23, 2025 | americanbankingnews.comFibroGen (FGEN) Expected to Announce Quarterly Earnings on MondayFibroGen (NASDAQ:FGEN) will be releasing earnings before the market opens on Monday, February 24.February 22, 2025 | marketbeat.comFibroGen (NASDAQ:FGEN) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of FibroGen in a research note on Thursday.February 21, 2025 | marketbeat.comStockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN)StockNews.com began coverage on shares of FibroGen in a research report on Friday. They issued a "hold" rating for the company.February 21, 2025 | marketbeat.comFibroGen to sell China business, extend cash runway to focus on cancer drugsFebruary 21, 2025 | bizjournals.comFibroGen stock soars on China unit saleFebruary 20, 2025 | in.investing.comThis Small Cap Soared Following Subsidiary Sale Announcement Worth $160MFebruary 20, 2025 | msn.comFibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 MillionFebruary 20, 2025 | finance.yahoo.comFibroGen China sale ‘shrewd strategic transaction,’ says H.C. WainwrightFebruary 20, 2025 | markets.businessinsider.comFibroGen sells China unit to AstraZeneca in deal worth $160 millionFebruary 20, 2025 | reuters.comFibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 MillionFebruary 20, 2025 | globenewswire.comFibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 5.2% in JanuaryFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,910,000 shares, a drop of 5.2% from the January 15th total of 3,070,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 2.3 days.February 18, 2025 | marketbeat.comSeveral Insiders Invested In FibroGen Flagging Positive NewsFebruary 4, 2025 | finance.yahoo.comFibroGen (NASDAQ:FGEN) Shares Pass Above 50 Day Moving Average - Here's What HappenedFibroGen (NASDAQ:FGEN) Stock Price Passes Above Fifty Day Moving Average - What's Next?January 21, 2025 | marketbeat.comPerspective Therapeutics appoints Graham as CFOJanuary 7, 2025 | markets.businessinsider.comFibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on FibroGen in a research note on Wednesday. They set a "hold" rating for the company.January 1, 2025 | marketbeat.comFibroGen initiated with a Buy at H.C. WainwrightDecember 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: FibroGen (FGEN) and Johnson & Johnson (JNJ)December 17, 2024 | markets.businessinsider.comFibroGen, Inc.: FibroGen Appoints David DeLucia as Chief Financial OfficerDecember 16, 2024 | finanznachrichten.deFibroGen Appoints David DeLucia as Chief Financial OfficerDecember 16, 2024 | globenewswire.comFibroGen (NASDAQ:FGEN) Stock, Option ChainNovember 15, 2024 | benzinga.comFibroGen Reports Strong Q3 Growth and Future PlansNovember 13, 2024 | markets.businessinsider.comFibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost ReductionsNovember 13, 2024 | finance.yahoo.comFibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call TranscriptNovember 12, 2024 | seekingalpha.comFibroGen Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comFibroGen to Report Third Quarter 2024 Financial ResultsNovember 4, 2024 | globenewswire.comDisc Medicine appoints Kaushik as Chief Technical OfficerOctober 23, 2024 | markets.businessinsider.comFibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ShiftsOctober 9, 2024 | finance.yahoo.comFibroGen to exit Mission Bay lease earlyOctober 4, 2024 | bizjournals.comFibroGen announces executive departures amid cost cutsSeptember 11, 2024 | uk.investing.comFGEN Sep 2024 2.500 callSeptember 8, 2024 | ca.finance.yahoo.comFibroGen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comFibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 9, 2024 | finance.yahoo.comFibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside PotentialAugust 8, 2024 | markets.businessinsider.comSan Francisco biotech company FibroGen guts staff after failed cancer trialsAugust 7, 2024 | msn.comFibroGen Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 6, 2024 | markets.businessinsider.comFGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q2 2024August 6, 2024 | investorplace.comOne Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment ProgramJuly 31, 2024 | benzinga.comS.F. biotech company to cut 75% of staff after clinical trial failuresJuly 31, 2024 | bizjournals.comFibroGen Layoffs 2024: What to Know About the Latest FGEN Job CutsJuly 31, 2024 | investorplace.comWhy Is FibroGen (FGEN) Stock Down 44% Today?July 31, 2024 | investorplace.comFibroGen to Cut U.S. Workforce by 75% on Termination of Pancreatic Cancer Pamrevlumab ProgramJuly 31, 2024 | marketwatch.comFibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate UpdateJuly 31, 2024 | finance.yahoo.comFibroGen stock plunges 48% post-market on failed drug studiesJuly 31, 2024 | msn.comFibroGen to Report Second Quarter 2024 Financial ResultsJuly 30, 2024 | globenewswire.comFibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%July 29, 2024 | finance.yahoo.comFibroGen Target of Unusually High Options Trading (NASDAQ:FGEN)FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) saw unusually large options trading on Monday. Stock traders bought 3,658 call options on the stock. This represents an increase of approximately 117% compared to the average daily volume of 1,686 call options.July 8, 2024 | marketbeat.comFibroGen, Inc. (NASDAQ:FGEN) Sees Significant Increase in Short InterestFibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 8,090,000 shares, an increase of 8.4% from the May 31st total of 7,460,000 shares. Based on an average trading volume of 2,320,000 shares, the days-to-cover ratio is presently 3.5 days.July 2, 2024 | marketbeat.com Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Media Mentions By Week FGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FGEN News Sentiment▼1.270.69▲Average Medical News Sentiment FGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FGEN Articles This Week▼21▲FGEN Articles Average Week Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Renovaro News Today Editas Medicine News Today Nuvectis Pharma News Today MacroGenics News Today Alector News Today Aclaris Therapeutics News Today FitLife Brands News Today Eupraxia Pharmaceuticals News Today Zentalis Pharmaceuticals News Today Organigram News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FGEN) was last updated on 3/4/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.